12,372 trials
Infections, Papillomavirus
Primary: Number of Subjects Seroprotected Against Diphtheria and Tetanus — 238; 233; 240; 233 Participants
Gastric Ulcer
Primary: Number of Subjects Monitored for Long-term Safety of PN 400 — 239 participants
HIV Infections
Primary: Time-weighted Average Change From Baseline Through Week 24 (DAVG24) in Plasma HIV-1 RNA — -1.580; -1.549 log10 copies/mL — p=0.55
Human Immunodeficiency Viruses
Primary: Architect HIV Combo Test Data for Clinical Specificity in Population at Low Risk for HIV Infection — 37; 14; 0; 6113 Blood Specimens
Osteoarthritis · Postoperative Pain
Primary: Subject Reported Worst Pain Score in Daily Diaries Using the Worst Pain Item of the Modified Brief Pain Inventory - Short Form (m-BPI-sf) — 7.041; 6.740; 7.079 scores on…
Possible Fungal Infection
Primary: Number of Participants With Proven or Probable Invasive Fungal Infections (IFI): Complete Case Analysis — 6; 9 participants — p=0.258
Healthy Volunteers
Primary: Bacterial Count of Skin Cultures for the 10% Povidone-iodine Period — 231 Colony-forming units per cm squared — p=<0.05
Influenza, Human
Primary: Geometric Mean Titers (GMTs) of Hemagglutination Inhibition (HI) Antibodies — 27.2; 22.8; 33.3; 45.9 titer
Asthma
Primary: The Number of All Randomized Subjects Reporting Adverse Events (AEs). — 109; 103; 56; 50 participants
Overactive Bladder
Primary: Safety Measurement Based on Adverse Events (AEs), Vital Signs, Clinical Laboratory Test, 12-lead ECG and Residual Urine Volume — 138; 91; 25; 22 Number of subjects
Hypertension
Primary: Number of Patients Achieving Target Blood Pressure at Week 14 From Baseline — 276; 270; 116; 87 Participants — p=0.118
Multiple Sclerosis
Primary: The Number of Subjects Rating the Suitability of RebiSmart at the End of 12-week Treatment Period for Self-injecting Rebif® New Formulation (RNF). — 73; 21; 8 participants
Acellular Pertussis · Tetanus · Diphtheria
Primary: Number of Subjects With Anti-diphtheria (Anti-D) Antibody Concentrations Greater Than or Equal to (≥) Protocol Specified Cut-off — 967; 489 Participants
Ankylosing Spondylitis
Primary: Number of Subjects Achieving Assessment in Ankylosing Spondylitis 20 (ASAS 20) at Week 12 — 30; 30; 30 Subjects
Schizophrenia · Psychotic Disorders
Primary: Mean Relapse Free Period(Risperidone LAI Versus Quetiapine) — 607; 533 days — p=<0.0001